Might sound silly, at 12 month highs- but given that all four tier 1 programs are all up for partnering and have passed recent hurdles (albeit low ones) the outlook is looking very bright.
With the recent spate of failures in RA and CHF drugs from big pharmaceuticals (Lilly and Novartis respectively) the spot light is being shone on regenerative medicine.
And the leader of the pack is non other than Mesoblast.
We could see a partner for CHF sooner rather than later, with the recent successful futility test and Novartis failure likely to make it a highly sought after program for the likes of Astrzeneca, Pfizer, even Novartis or Lilly!
Nasdaq seems to be picking up on the sentiment quicker than the ASX, but that is expected with the Nasdaq having a greater appreciation of the market that MSB is looking to crack into.
MSB looks cheap
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
0.078(7.99%) |
Mkt cap ! $1.196B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.06 | 99.0¢ | $3.864M | 3.759M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 91326 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 117327 | 18 |
View Market Depth
| Last trade - 14.43pm 04/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |